Last reviewed · How we verify
NCT07105982
Radiolabeled TSPO Targeted Molecular Probe in AMI
trial in Acute Myocardial Infarction (AMI) in 8 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 1 September 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2026 |
Conditions studied
- Acute Myocardial Infarction (AMI) — all drugs for Acute Myocardial Infarction (AMI) →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Adults 18 to 75, any sex, with Acute Myocardial Infarction (AMI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 for inflammation imaging associated with acute myocardial infarction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07105982
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction (AMI)
Currently open trials in the same condition.
- NCT07400601 — A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital · recruiting
- NCT07208006 — Very Early PCSK9 Inhibition for Acute Myocardial Infarction · NA · recruiting
- NCT07537296 — Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction · recruiting
- NCT07276282 — Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction · Phase 3 · recruiting
- NCT07293923 — Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock · NA · recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07105982 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07105982.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing